A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis

Trial Profile

A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms BE ACTIVE
  • Sponsors UCB Biopharma
  • Most Recent Events

    • 20 Dec 2017 Positive top line results published in a UCB Media Release
    • 20 Dec 2017 According to a UCB media release, after complition of 12 week study, patients will continue a 36-week dose-blind treatment period, a total duration of 48 week study.
    • 20 Dec 2017 Primary endpoint has been met. (ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12), according to a UCB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top